RADVAX: A Stratified Phase I/II Dose Escalation Trial of Hypofractionated Radiotherapy Followed by Ipilimumab in Metastatic Melanoma.

Trial Profile

RADVAX: A Stratified Phase I/II Dose Escalation Trial of Hypofractionated Radiotherapy Followed by Ipilimumab in Metastatic Melanoma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms RADVAX
  • Most Recent Events

    • 22 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 30 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top